NCT06545097View on ClinicalTrials.gov

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 3, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

February 28, 2025

Conditions
Acute Pain
Interventions
DRUG

Cebranopadol

Once a day for 2 days; once daily on Day1 (with Cebranopadol 200ug).

DRUG

Cebranopadol

Once daily on Day 2 (with Cebranopadol 400 ug)

DRUG

Placebo

Once daily for 2 days

Trial Locations (4)

33014

ALLEVIATE 1 Site 001112, Miami

72211

ALLEVIATE 1 Site 001106, Little Rock

77401

ALLEVIATE 1 Site 001110, Bellaire

78240

ALLEVIATE 1 Site 001111, San Antonio

All Listed Sponsors
lead

Tris Pharma, Inc.

INDUSTRY

NCT06545097 - A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty | Biotech Hunter | Biotech Hunter